A Study to Demonstrate Non-inferior Immunogenicity of Yuxi Walvax MPV ACYW® Vaccine in Healthy Subjects Aged 2-10 Years
Primary Purpose
Neisseria Meningitides Meningitis
Status
Completed
Phase
Phase 4
Locations
Mali
Study Type
Interventional
Intervention
Yuxi Walvax MPV ACYW® vaccine
Sanofi Pasteur Menactra® vaccine
Sponsored by
About this trial
This is an interventional prevention trial for Neisseria Meningitides Meningitis focused on measuring Neisseria Meningitidis, Non-inferior immunogenicity, Safety
Eligibility Criteria
Inclusion Criteria:
- Age 2 to 10 years of age (both included)
- Written informed consent obtained from the mother, father, or guardian of the child.
- Free of obvious health problems and be fully vaccinated according local EPI schedule as established by medical history including physical examination and clinical judgment of the investigator.
- Mother, father, or guardian capable and willing to bring their child or to receive home visits for their child for all follow-up visits.
- Residence in the study area during the study period.
Exclusion Criteria:
- Vaccination against group A,C,Y,W Neisseria meningitidis in the previous 3 months
- History of allergic disease or known hypersensitivity to any component of the two study vaccines.
- History of serious adverse reactions following administration of vaccines included in the local program of immunization.
- Administration of any other vaccine within 30 days prior to administration of study vaccines or planned vaccination during the first four weeks after the study vaccination.
- Use of any investigational or nonregistered product within 60 days prior to the administration of study vaccines.
- Administration of immunoglobulins and/or any blood products or planned administration during the study participation period.
- Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying agents since birth (including systemic or inhaled corticosteroids, this means prednisone, or equivalent, ≥0.5 mg/kg/day; topical steroids are allowed).
- A family history of congenital or hereditary immunodeficiency.
- History of meningitis or seizures, or any neurological disorder, convulsions, or active tuberculosis.
- Major congenital defects or serious chronic illness, including malnutrition (i.e., weight less than or equal to 3 standard deviations below the mean for 2-5 years old) and immunodeficiency disorder (as per investigator's judgment)
- Acute disease at the time of enrollment (acute disease being defined as the presence of a moderate or severe illness with or without fever) resulting in a temporary exclusion.
- Acute or chronic, clinically significant pulmonary, cardiovascular, hepatic, or renal functional abnormality, as determined by medical history, physical examination, or laboratory tests, which in the opinion of the investigator might interfere with the well-being of the subject study objectives.
- Any condition or criterion that in the opinion of the investigator might compromise the well-being of the subject or the compliance with study procedures or interfere with the outcome of the study
Sites / Locations
- Centre pour le Développement des Vaccins du Mali
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
Walvax MPV ACYW® vaccine group
Sanofi Pasteur Menactra® vaccine group
Arm Description
Outcomes
Primary Outcome Measures
Antibody response at Day 30 post-vaccination
Percentage of subjects with rSBA (Serum Bactericidal Activity using baby rabbit complement) titer ≥1:128 to A,C,Y,W meningococcal capsular polysaccharide in both vaccine groups 30 days after immunization
Secondary Outcome Measures
Percentages of subjects with post-immunization local and systemic reactions within 7 days following vaccination in both vaccine groups
Percentages of subjects with reported Adverse Events within 30 days following vaccination in both vaccine groups
Percentages of subjects with reported SAEs within 6 months following vaccination in both vaccine groups
rSBA Geometric mean antibody titers to A,C,Y,W meningococcal capsular polysaccharide in both vaccine groups
Percentage of subjects with rSBA titer ≥1:8 to A,C,Y,W meningococcal capsular polysaccharide in both vaccine groups 30 days after immunization
Seroconversion rates as defined by proportion of subjects with ≥ 4-fold increase 30 days after immunization with respect to baseline of rSBA antibodies to A,C,Y,W meningococcal capsular polysaccharide in both vaccine groups 30 days after immunization
Seroconversion rates as defined by proportion of subjects with ≥ 2-fold increase 30 days after immunization with respect to baseline of rSBA antibodies to A,C,Y,W meningococcal capsular polysaccharide in both vaccine groups
Full Information
NCT ID
NCT04450498
First Posted
June 23, 2020
Last Updated
July 5, 2023
Sponsor
Walvax Biotechnology Co., Ltd.
1. Study Identification
Unique Protocol Identification Number
NCT04450498
Brief Title
A Study to Demonstrate Non-inferior Immunogenicity of Yuxi Walvax MPV ACYW® Vaccine in Healthy Subjects Aged 2-10 Years
Official Title
A Phase IV Randomized, Observer-blind, Controlled Study to Demonstrate Non-inferior Immunogenicity of Yuxi Walvax MPV ACYW® Vaccine as Compared to Sanofi Pasteur Menactra® Vaccine in Healthy Subjects Aged 2-10 Years
Study Type
Interventional
2. Study Status
Record Verification Date
July 2023
Overall Recruitment Status
Completed
Study Start Date
December 23, 2020 (Actual)
Primary Completion Date
July 30, 2021 (Actual)
Study Completion Date
July 30, 2021 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Walvax Biotechnology Co., Ltd.
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
5. Study Description
Brief Summary
This is a phase IV, single-center, observer-blind, randomized, controlled vaccine trial in 2 to 10 years old healthy subjects. Each participant will receive a single intramuscular injection of one of the two vaccines either MPV ACYW® vaccine or Menactra ® vaccine according to the vaccine group assignment and will be followed up for one month for immunogenicity evaluation and for 6 months for safety evaluation.
Statistical Hypothesis:
H0: Seroconversion rate of test group is inferior to that of control group HA: Seroconversion rate of test group is non-inferior to that of control group Sample size calculation: the sample size was calculated based on non-inferiority test with alpha level of 0.025 and 80% power, assuming seroconversion rate in control group was 95% with non-inferiority margin at 10%. The sample size required for the study is 124 per arm. After adjusting for 5% drop-out, the final sample size required is 130 per arm.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Neisseria Meningitides Meningitis
Keywords
Neisseria Meningitidis, Non-inferior immunogenicity, Safety
7. Study Design
Primary Purpose
Prevention
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Model Description
At Day 0, eligible subjects will be randomized in a 1:1 ratio into either Walvax MPV ACYW® vaccine group (130 subjects) or Sanofi Pasteur Menactra ® vaccine group (130 subjects). A randomization list containing subject numbers and vaccine group assignments will be provided to the investigator. Each participant will receive a single intramuscular injection of one of the two vaccines either MPV ACYW® vaccine or Menactra ® vaccine according to the vaccine group assignment and will be followed up for one month for immunogenicity evaluation and for 6 months for safety evaluation.
Masking
Investigator
Masking Description
The study will be carried out in an observer blind fashion until database is locked with data collected until Day 30 (Visit 3) after vaccination. The clinical study material, i.e. vaccine packs, will be packaged and encoded according to the randomization list (see Appendix B for example of vaccine labels). At study site, the investigator will assign unblinded designated person(s) responsible for vaccine handling, administration ("Vaccinator") and accountability to ensure that blinding is protected throughout the study procedures and that no other site personnel involved in the conduct of the study has access to the information. After assessment of eligibility of a new subject, the investigator will complete a form that the subject will take to the "vaccinator". The "vaccinator" will administer the vaccine according to the randomization list to the subject without informing neither the subject nor the investigator of the randomization group, i.e. the nature of the vaccine.
Allocation
Randomized
Enrollment
260 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Walvax MPV ACYW® vaccine group
Arm Type
Experimental
Arm Title
Sanofi Pasteur Menactra® vaccine group
Arm Type
Active Comparator
Intervention Type
Biological
Intervention Name(s)
Yuxi Walvax MPV ACYW® vaccine
Intervention Description
Walvax MPV ACYW vaccine is a sterile formulation of polysaccharide A,C,Y,W-135. One dose of 0.5 mL contains 50 µg of each A,C,Y,W-135 purified polysaccharide. The vaccine is presented in two vials: one containing the lyophilized cake of A,C,Y,W purified polysaccharides and the other the sterile water for injection as diluent. After reconstitution the one dose of 0.5 mL is ready for subcutaneous injection. The antigen content is similar to other internationally marketed polysaccharide vaccines that have been in use for decades as Menomune® Sanofi and Mencevax® Pfizer , all containing 50 µg of each A,C,Y,W purified polysaccharide that as one dose schedule are recommended for use in subjects > 2 years of age and have shown to be safe and immunogenic.
Intervention Type
Biological
Intervention Name(s)
Sanofi Pasteur Menactra® vaccine
Intervention Description
The vaccine presentation is a full liquid formulation in a single dose of 0.5 mL with the following composition: Meningococcal group A polysaccharide 4 µg; Meningococcal group C polysaccharide 4 µg; Meningococcal group Y polysaccharide 4 µg; Meningococcal group W polysaccharide 4 µg; Diphtheria toxoid protein total 48 µg; Sodium phosphate 0.7 mg; Sodium chloride 4.35 mg.
Primary Outcome Measure Information:
Title
Antibody response at Day 30 post-vaccination
Description
Percentage of subjects with rSBA (Serum Bactericidal Activity using baby rabbit complement) titer ≥1:128 to A,C,Y,W meningococcal capsular polysaccharide in both vaccine groups 30 days after immunization
Time Frame
Day 30 post-vaccination
Secondary Outcome Measure Information:
Title
Percentages of subjects with post-immunization local and systemic reactions within 7 days following vaccination in both vaccine groups
Time Frame
Day 7 post-vaccination
Title
Percentages of subjects with reported Adverse Events within 30 days following vaccination in both vaccine groups
Time Frame
Day 30 post-vaccination
Title
Percentages of subjects with reported SAEs within 6 months following vaccination in both vaccine groups
Time Frame
Day 30 to Day 180 post-vaccination (end of study visit)
Title
rSBA Geometric mean antibody titers to A,C,Y,W meningococcal capsular polysaccharide in both vaccine groups
Time Frame
Day 30 post-vaccination
Title
Percentage of subjects with rSBA titer ≥1:8 to A,C,Y,W meningococcal capsular polysaccharide in both vaccine groups 30 days after immunization
Time Frame
Day 30 post-vaccination
Title
Seroconversion rates as defined by proportion of subjects with ≥ 4-fold increase 30 days after immunization with respect to baseline of rSBA antibodies to A,C,Y,W meningococcal capsular polysaccharide in both vaccine groups 30 days after immunization
Time Frame
Day 30 post-vaccination
Title
Seroconversion rates as defined by proportion of subjects with ≥ 2-fold increase 30 days after immunization with respect to baseline of rSBA antibodies to A,C,Y,W meningococcal capsular polysaccharide in both vaccine groups
Time Frame
Day 30 post-vaccination
10. Eligibility
Sex
All
Minimum Age & Unit of Time
2 Years
Maximum Age & Unit of Time
10 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Age 2 to 10 years of age (both included)
Written informed consent obtained from the mother, father, or guardian of the child.
Free of obvious health problems and be fully vaccinated according local EPI schedule as established by medical history including physical examination and clinical judgment of the investigator.
Mother, father, or guardian capable and willing to bring their child or to receive home visits for their child for all follow-up visits.
Residence in the study area during the study period.
Exclusion Criteria:
Vaccination against group A,C,Y,W Neisseria meningitidis in the previous 3 months
History of allergic disease or known hypersensitivity to any component of the two study vaccines.
History of serious adverse reactions following administration of vaccines included in the local program of immunization.
Administration of any other vaccine within 30 days prior to administration of study vaccines or planned vaccination during the first four weeks after the study vaccination.
Use of any investigational or nonregistered product within 60 days prior to the administration of study vaccines.
Administration of immunoglobulins and/or any blood products or planned administration during the study participation period.
Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying agents since birth (including systemic or inhaled corticosteroids, this means prednisone, or equivalent, ≥0.5 mg/kg/day; topical steroids are allowed).
A family history of congenital or hereditary immunodeficiency.
History of meningitis or seizures, or any neurological disorder, convulsions, or active tuberculosis.
Major congenital defects or serious chronic illness, including malnutrition (i.e., weight less than or equal to 3 standard deviations below the mean for 2-5 years old) and immunodeficiency disorder (as per investigator's judgment)
Acute disease at the time of enrollment (acute disease being defined as the presence of a moderate or severe illness with or without fever) resulting in a temporary exclusion.
Acute or chronic, clinically significant pulmonary, cardiovascular, hepatic, or renal functional abnormality, as determined by medical history, physical examination, or laboratory tests, which in the opinion of the investigator might interfere with the well-being of the subject study objectives.
Any condition or criterion that in the opinion of the investigator might compromise the well-being of the subject or the compliance with study procedures or interfere with the outcome of the study
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Samba O Sow, MD, MSc
Organizational Affiliation
Director General
Official's Role
Principal Investigator
Facility Information:
Facility Name
Centre pour le Développement des Vaccins du Mali
City
Bamako
Country
Mali
12. IPD Sharing Statement
Plan to Share IPD
No
Citations:
PubMed Identifier
37401618
Citation
Sow SO, Tapia MD, Haidara FC, Diallo F, Traore Y, Traore A, Kodio M, Borrow R, Townsend-Payne K, Yuan L, Yang S, Shi L, Chen J, Fang G, Lin J, Hu R, Viviani S, Huang Z. Safety and immunogenicity of quadrivalent meningococcal polysaccharide vaccine (MPV ACYW135) compared with quadrivalent meningococcal conjugate vaccine (Menactra(R)) in Malian children. Hum Vaccin Immunother. 2023 Aug 1;19(2):2230829. doi: 10.1080/21645515.2023.2230829. Epub 2023 Jul 4.
Results Reference
result
Learn more about this trial
A Study to Demonstrate Non-inferior Immunogenicity of Yuxi Walvax MPV ACYW® Vaccine in Healthy Subjects Aged 2-10 Years
We'll reach out to this number within 24 hrs